The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.
Condition or disease : hypertension Intervention/treatment Drug : AD-209-H Drug : AD-209-M Drug : AD-209-L Drug : Placebo Drug : Amlodipine Drug : Telmisartan Phase : Phase 2
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
176
PO, Once daily(QD), 8weeks
PO, Once daily(QD), 8weeks
PO, Once daily(QD), 8weeks
Korea University Guro Hospital
Seoul, South Korea
1. Change rate of MSSBP
Change from baseline in mean sitting systolic blood pressure
Time frame: [ Time Frame: baseline, 8 weeks ]
1. Change rate of MSSBP
Change from baseline in mean sitting systolic blood pressure
Time frame: [ Time Frame: baseline, 4 weeks ]
2. Change rate of MSDBP
Change from baseline in mean sitting diastolic blood pressure
Time frame: [ Time Frame: baseline, 4 weeks, 8 weeks ]
3. Proportion of BP normalization MSSBP/MSDBP < 140/90 mmHg MSSBP/MSDBP < 130/80 mmHg (Diabetes or Chronic renal disease)
Proportion of subjects achieving blood pressure control
Time frame: [ Time Frame: 4 weeks, 8 weeks ]
4.Reaction rate of BP
Proportion of reduction from baseline in MSSBP/MSDBP ≥ 20/10 mmHg
Time frame: [ Time Frame: baseline, 4 weeks, 8 weeks ]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
PO, Once daily(QD), 8weeks